NCT04554004

Brief Summary

Coronary artery microvascular disease (CMVD) lacks reliable and non-invasive quantitative diagnosis methods. Improving coronary microcirculation has become one of the main goals of coronary heart disease treatment. In this study, by establishing the key influencing factors of myocardial microcirculation perfusion, an accurate three-dimensional reconstruction method of coronary artery was established, and a non-invasive coronary microcirculation resistance index (CT-IMR) calculation method based on computational fluid method mechanics was established. At the same time, a phase I single-center clinical verification and a multi-center clinical verification of the non-invasive coronary microcirculation function precision assessment system were carried out, and a non-invasive coronary microcirculation detection system and technology were established.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
295

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 8, 2020

Completed
10 days until next milestone

First Posted

Study publicly available on registry

September 18, 2020

Completed
2.2 years until next milestone

Study Start

First participant enrolled

December 15, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

June 4, 2025

Status Verified

June 1, 2025

Enrollment Period

2 years

First QC Date

September 8, 2020

Last Update Submit

June 1, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • sensitivity and specificity

    The sensitivity and specificity of CT-IMR in the diagnosis of microcirculation dysfunction were studied.

    up to 12 months

Secondary Outcomes (1)

  • diagnostic

    up to 12 months

Study Arms (1)

Study group

EXPERIMENTAL

All consecutive patients undergoing outine CT angiography and dynamic CT-myocardial perfusion imaging(MPI) will be potentially eligible for inclusion in the trial. Assessment of coronary stenosis severity using invasive fractional flow reserve (FFR) and the status of myocardial microcirculation perfusion including coronary flow reserve (CFR) and index of microvascular resistance (IMR) will be performed as part of invasive coronary angiography(CAG).

Diagnostic Test: CCTA, CT-MPI, DSA, FFR

Interventions

CCTA, CT-MPI, DSA, FFRDIAGNOSTIC_TEST

The patients who enrolled the study will undergo coronary CT angiography(CCTA), dynamic CT-MPI, invasive coronary angiography and invasive computation of fractional flow reserve (FFR)

Study group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject must be older than 18 years
  • Written informed consent available
  • Subject is indicated for invasive coronary angiography
  • Subject need to be taken within 30 days after enrolment

You may not qualify if:

  • Previous PCI or CABG
  • Subject is not eligible for measuring IMR
  • Complicated complex congenital heart disease
  • Artificial pacemaker or internal defibrillator leads implanted
  • Implanted artificial heart valve
  • Severe arrhythmia including complete AV block, ventricular arrhythmia
  • Impaired chronic renal function (serum creatinine\>1.5ULN)
  • Allergic to iodine
  • Pregnancy
  • Body mass index \>35 kg/m2
  • Left ventricle is markedly thickened
  • Needs for emergency procedures
  • Severe distortion of in the blood vessel
  • Unstable haemodynamics including abrupt chest pain cardiogenic shock, unstable blood pressure (systolic \< 90mmHg), severe congestive heart failure or pulmonary edema
  • Life-threatening diseases (life expectancy \< 2 months)
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

First People's Hospital of Hangzhou

Hanzhou, Zhejiang, China

Location

MeSH Terms

Conditions

Microvascular AnginaCoronary Artery Disease

Condition Hierarchy (Ancestors)

Angina PectorisMyocardial IschemiaHeart DiseasesCardiovascular DiseasesVascular DiseasesCoronary DiseaseArteriosclerosisArterial Occlusive Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
professor

Study Record Dates

First Submitted

September 8, 2020

First Posted

September 18, 2020

Study Start

December 15, 2022

Primary Completion

December 31, 2024

Study Completion

December 31, 2024

Last Updated

June 4, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

Individual participant data that underlie the results reported in this article after deidentification (text, table, figures, and appendices).

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
When will data be available (start and end dates)?Beginning 3 months. No end data.
Access Criteria
Proposals should be directed to zdsyhjy0902@zju.edu.cn. To gain access, data requestors will need to sign a data access agreement.

Locations